Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in Advanced Solid Tumors
NCT03529526Phase 1Unknown
- Sponsor
- Alphamab Oncology
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erfonrilimab in solid tumor (advanced stage), sponsored by Alphamab Oncology. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03529526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529526.